BioCryst Pharmaceuticals Inc.

07/01/2022 | Press release | Distributed by Public on 07/01/2022 05:10

BioCryst Presents New Data Demonstrating Consistently Low Attack Rates Among HAE Patients After Switching to ORLADEYO® (berotralstat)